If you have been reading about MOD GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-16. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
== Biomolecular structure == A fibrous protein is composed of long, repetitive chains of amino acids that are intertwined to form structures resembling rods or wires. These proteins are often insoluble in water, meaning they do not dissolve. This insolubility is due to the arrangement of their amino acids; many of the amino acids that are exposed on the surface of the protein are hydrophobic (water-repelling), which causes the proteins to clump together, or aggregate, in a watery environment. A fibrous protein's peptide sequence often has limited residues with repeats; these can form unusual secondary structures, such as a collagen helix. The structures often feature cross-links between chains (e.g., cys-cys disulfide bonds between keratin chains). Fibrous proteins tend not to denature as easily as globular proteins. Miroshnikov et al. (1998) are among the researchers who have attempted to synthesize fibrous proteins.
Rutherfordium is a synthetic chemical element; it has symbol Rf and atomic number 104. It is named after physicist Ernest Rutherford. As a synthetic element, it is not found in nature and can only be made in a particle accelerator. It is radioactive; the most stable known isotope, 267Rf, has a half-life of about 48 minutes. In the periodic table, it is a d-block element and the second of the fourth-row transition elements. It is in period 7 and is a group 4 element. Chemistry experiments have confirmed that rutherfordium behaves as the heavier homolog to hafnium in group 4. The chemical properties of rutherfordium are known only partly. They compare well with the other group 4 elements, though some calculations had indicated that the element might show significantly different properties due to relativistic effects. In the 1960s, small amounts of rutherfordium were produced at Joint Institute for Nuclear Research (JINR) in the Soviet Union and at Lawrence Berkeley National Laboratory in California. Priority of discovery and hence the name of the element was disputed between Soviet and American scientists, and it was not until 1997 that the International Union of Pure and Applied Chemistry (IUPAC) established rutherfordium as the official name of the element.
On 3 April, Iranian forces shot down a US Air Force F-15E Strike Eagle fighter jet over the country, with the wreckage falling in the Kohgiluyeh and Boyer-Ahmad province of Iran, the first incident of its kind in more than 20 years. The pilot was rescued that same day, but the WSO remained missing and was rescued alive 48 hours later in a "high-stake" operation involving US special forces supported by 155 aircraft. A US A-10 "Warthog" aircraft was downed and its single crew member ejected near the Strait of Hormuz and was rescued. Iran released a video that, according to Iran, showed the downing of the aircraft using a surface-to-air missile. On the same day, Tehran's Shahid Beheshti University was hit by airstrikes, making the total number of universities hit to more than 30, according to the Iranian Minister of Science.
Sources: en.wikipedia.org
The presidency of Pedro Castillo began with Castillo's inauguration as the president of Peru on 28 July 2021, the Peruvian Independence Day. In the 2021 Peruvian general election, Castillo, a school teacher and union organizer, won the presidential election against the right-wing candidate Keiko Fujimori of Popular Force by a 45,000 margin in the runoff. In the congressional elections, Castillo's party, Free Peru, did not get a majority in the Congress of the Republic of Peru.
While Fenn was working with Monsanto, the company's research was focused on the production of phosphoric acid and polychlorinated biphenyls (PCBs). Fenn and his colleagues at Monsanto were largely unaware of the health hazards posed by PCBs, indeed because of their inertness, they "practically bathed in the stuff". After spending several more years doing various industrial research, Fenn was looking to get back into the academic world. He had the opportunity to go to Princeton University, where he became the director of Project SQUID. Fenn did not start his Nobel-winning research until later in his career. He was semi-retired when he first published his research on electrospray ionization for mass spectrometry. Fenn felt that his work in electrospray ionization received "a kick in the pants" when proteomics emerged. In 2001, more than 1700 papers on proteomics were published, many using electrospray ionization. Electrospray ionization provides a way to get accurate information about the mass of a large molecule very quickly, even when it is in a mixture of other molecules. The liquid sample is introduced into an electrospray source (at atmospheric pressure) and desolvated with a flow of heated nitrogen gas. This forms small droplets which evaporate in a region under vacuum, which increases the charge on the droplets. For large molecules like proteins, this often results in multiply charge species. Increasing the charge on the molecules, decreased the mass-to-charge ratio, which allows the mass to be more easily determined.
The band was scheduled to tour during the summer of 1994 with Metallica, Suicidal Tendencies, Danzig, and Fight, as well as a slot during Woodstock '94, but while in rehearsal for the tour, Staley began using heroin again. Staley's condition prompted the other band members to cancel all scheduled dates one day before the start of the tour, putting the band on hiatus. Alice in Chains was replaced by Candlebox on the tour. Susan Silver's management office sent out a statement saying that the decision to withdraw from the Metallica tour and Woodstock was "due to health problems within the band." Shortly after withdrawing, the band broke up for six months, with Kinney telling Rolling Stone in 1996, "Nobody was being honest with each other back then. If we had kept going, there was a good chance we would have self-destructed on the road, and we definitely didn't want that to happen in public."
Sources: en.wikipedia.org
== Description == Within a group of people, a command hierarchy defines who carry out orders based on group members' authority. In sociology, command hierarchy is seen as the most visible element of a "power network". In this model, social capital is viewed as being mobilized in response to orders that move through the hierarchy leading to the phrase "command and control".
=== Additive for cosmetics === The juice can be used in skin creams due to its high polyphenol, vitamin and protein content. Hemp salt unfolds its soothing effect on neurodermatitis as a bath additive. Hemp juice is now appearing as an inactive ingredient in many cosmetic products.
Diabetes was one of the first diseases described, with an Egyptian manuscript from c. 1500 BCE mentioning "too great emptying of the urine". The Ebers papyrus includes a recommendation for a drink to take in such cases. The first described cases are believed to have been type 1 diabetes. The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek Apollonius of Memphis. The disease was considered rare during the time of the Roman Empire, with Galen commenting he had seen only two cases during his career. This is possibly due to the diet and lifestyle of the people of that time, or because the clinical symptoms were only observed during the advanced stage of the disease. Galen named the disease "diarrhea of the urine" (diarrhea urinosa). Indian physicians around the sixth century CE identified the disease and classified it as madhumeha or "honey urine", noting the urine would attract ants. The earliest surviving work with a detailed reference to diabetes is that of Aretaeus of Cappadocia (2nd or early 3rd century CE). He described the symptoms and the course of the disease, which he attributed to moisture and coldness, reflecting his beliefs in the "Pneumatic School" of medicine. He hypothesized a correlation between diabetes and other diseases, and he discussed differential diagnosis from a snakebite, which also provoked excessive thirst. His work remained unknown in the West until 1552, when the first Latin edition was published in Venice.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.